Evommune, Inc. Debt Securities, Held-to-maturity, Noncurrent
Evommune, Inc. (EVMN) had Debt Securities, Held-to-maturity, Noncurrent of $87.21 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:HeldToMaturitySecuritiesNoncurrent · last filed 2026-08-06
- 2026-06-30: Debt Securities, Held-to-maturity, Noncurrent $87.21M.
- 2026-03-31: Debt Securities, Held-to-maturity, Noncurrent $95.55M.
- 2025-12-31: Debt Securities, Held-to-maturity, Noncurrent $67.49M.
| Period end | Debt Securities, Held-to-maturity, Noncurrent |
|---|---|
| 2026-06-30 | $87.21M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $95.55M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $67.49M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |